Milo Biotechnology is a Cleveland, OH based company developing therapies to increase muscle strength and prevent muscle atrophy. The company’s lead program is a skeletal muscle specific transgene of the protein follistatin. The follistatin 344 transgene is delivered via an adeno-associated virus to achieve long lasting and potent expression in muscle. Milo is currently engaged in three clinical studies for rare muscular dystrophies. Milo Biotechnology’s therapy is based on adeno-associated virus (AAV) delivery of follistatin. AAVs are small, non-pathogenic carriers that can be tailored to deliver sustained administration of follistatin via a single dose.
Member count: 11-50
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Rev1 Ventu... | rev1ventur... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 22.09.2016 | Milo Biote... | Milo Biotechnology, a Clevelan... | USA | - | finsmes.co... |
| 26.02.2013 | Muscular d... | This approach to treating musc... | - | - | medcitynew... |
| 16.02.2012 | Milo Biote... | Milo Biotechnology, a Clevelan... | funding S... | - | finsmes.co... |
| - | Muscular d... | With a new $300,000 Phase I SB... | - | - | medcitynew... |